LEADS BIOLABS-B (09887): Presented the latest clinical data for Vilixin at the 2026 Jefferies Global Healthcare Conference
LEADS BIOLABS-B (09887) announced that on November 19, 2026, Dr. Kang Xiaoqiang, founder, chairman and chief executive officer of the Company, was invited to attend the 2026 Jefferies Global Healthcare Conference held in London, where he presented the latest clinical and safety data for our independently developed Vilixin (opamtisumumab, an anti-PD-L1/4-1BB bispecific antibody). The presentation covered the mechanistic basis and clinical evidence for long-tail survival benefit, as well as efficacy and safety across tumor types, comprehensively presenting the differentiated advantages of Vilixin to global pharmaceutical companies and investors, and demonstrating the global competitiveness of this next-generation immuno-oncology (IO 2.0) drug candidate developed in China.
LEADS BIOLABS-B (09887) announced that on November 19, 2026, Dr. Kang Xiaoqiang, the Company's founder, chairman and chief executive officer, was invited to attend the 2026 Jefferies Global Healthcare Conference held in London, where he presented the latest clinical and safety data for our independently developed Vilixin (opamtisumumab, an anti-PD-L1/4-1BB bispecific antibody). The presentation covered the mechanistic basis and clinical evidence for long-tail survival benefit, as well as cross-tumor efficacy and safety, comprehensively presenting Vilixin's differentiated advantages to global pharmaceutical companies and investors, and demonstrating the global competitiveness of this next-generation immuno-oncology (IO 2.0) candidate drug developed in China.
The latest data support Vilixin's potential as a next-generation pan-tumor IO 2.0 backbone therapy with clear long-term survival benefit. Results from multiple clinical trials fully demonstrate its strong ability to address the limitations of traditional immunotherapy, including limited response rates and difficulty in benefiting patients with cold tumors and PD-L1-negative or low-expression patients. From deep responses in large indications to doubling-type breakthroughs in overall survival (OS) versus historical data in refractory cold tumors, these data collectively solidify Vilixin's clinical positioning as a potential pan-tumor IO 2.0 backbone therapy and outline five key value dimensions of a next-generation immuno-oncology backbone therapy.
(1) Long-term survival potential and managing cancer as a chronic disease: To date, all indications with sufficiently long follow-up, including first-line combination with chemotherapy and late-line monotherapy, have demonstrated long-tail survival benefit. This includes: median OS in extrapulmonary neuroendocrine carcinoma (EP-NEC) doubled versus historical data; median OS in small cell lung cancer (SCLC) still not mature after 18 months of follow-up; encouraging survival trends in the first 18 patients of the Phase II non-small cell lung cancer (NSCLC) study after more than 12 months of follow-up; and significantly prolonged OS after mature follow-up for late-line monotherapy in biliary tract cancer, liver cancer, ovarian cancer (OC) and other cold tumorspotentially driving the transformation of advanced tumors into long-term manageable chronic diseases.
(2) Broad-spectrum efficacy: Breakthrough efficacy has been demonstrated in seven tumor types to date, supporting its potential as a next-generation broad-spectrum immunotherapy backbone therapy.
(3) Cold tumor breakthrough: Breakthrough efficacy has been demonstrated in five immunologically cold tumor types to date, with the potential to overcome the efficacy limitations of first-generation immunotherapy.
(4) Broad patient population coverage: Consistent benefit trends have been observed in PD-L1-positive, negative and low-expression patients, with the potential to cover a broader patient population.
(5) Excellent safety: More than 800 patients have been treated, with no dose-limiting toxicities observed. The overall safety profile is similar to that of PD-(L)1 monoclonal antibodies, supporting long-term dosing in a broader patient population.
At this conference, the Company disclosed for the first time its plan to initiate multiple antibody-drug conjugate (ADC) combination therapy programs in 2027, including combinations with internally independently developed next-generation bispecific ADCs and T-cell engager ADCs (TCE-ADCs), as well as combinations with industry-leading ADCs.
Vilixin adopts a molecular design with high affinity for PD-L1 and extremely low affinity for 4-1BB, achieving conditional activation of 4-1BB in the tumor microenvironment and providing synergistic effects of immune checkpoint blockade and co-stimulation only within the tumor microenvironment. This design reshapes the immunosuppressive tumor microenvironment while avoiding hepatotoxicity caused by 4-1BB activation in normal tissues. It significantly promotes T-cell activation and proliferation, stimulates the secretion of large amounts of cytokines, and substantially reduces the number of regulatory T cells. More critically, it generates long-lived memory T cells. These long-lived memory T cells continue to provide immune surveillance after drug discontinuation, which is the fundamental basis for Vilixin's ability to overcome the limitations of traditional immunotherapy and bring durable survival benefit to patients.
It has demonstrated significant clinical OS benefit. To date, all indications with sufficiently long follow-up, including first-line combination with chemotherapy and late-line monotherapy, have shown long-tail survival benefit. This includes: median OS in EP-NEC doubled versus historical data; OS in SCLC further prolonged; and long-tail trends in late-line monotherapy across three indications.
EP-NEC is currently the indication with the most mature survival data for Vilixin. Long-term survival data have been read out from both first-line and late-line studies, validating Vilixin's OS benefit (the relevant data were published as a late-breaking abstract and preferred paper presentation at the 2026 European Society for Medical Oncology (ESMO) Congress). In the pivotal monotherapy registration study of Vilixin for third-line or later EP-NEC (n=96), median follow-up was 16.3 months and median OS was 8.7 months, compared with historical data of approximately 3 to 4 months. For Vilixin combined with chemotherapy in first-line EP-NEC (n=69), median follow-up was 21.2 months, median OS was not mature, and the 18-month OS rate was 55.7%. Historical median OS for first-line chemotherapy was 11.5 to 12.5 months.
Meanwhile, as of now, median follow-up in SCLC has reached 18 months, OS data are not yet mature, and an encouraging long-term survival trend is emerging. In addition, follow-up of the late-line monotherapy cohort in the early basket trial has exceeded two years, OS data are mature, and all three tumor types have shown encouraging long-tail benefit trends. In third-line or later biliary tract cancer (BTC) (n=31), median OS was 7.5 months, longer than the 6.2 months for mFOLFOX and 5.3 months for regorafenib in historical second-line data. In late-line hepatocellular carcinoma (HCC) (n=14, previously treated with immunotherapy), median OS was 13.3 months. Historical second-line data were 10.6 months for regorafenib and 10.2 months for cabozantinib. In second-line or later OC (n=11), median OS was 26.5 months. Historical second-line data for bevacizumab combined with chemotherapy were 13.3 months.
The conference also updated follow-up data for the first 18 NSCLC patients. With follow-up extended to 12.3 months, tumor responses continued to deepen, likewise suggesting Vilixin's long-tail potential. Specifically, the data showed the following positive signals. All subtypes demonstrated differentiated advantages over standard of care and numerically exceeded the historical median progression-free survival (mPFS) for the same indications. Historical mPFS was approximately 3 to 4 months for previously immunotherapy-treated non-squamous NSCLC, approximately 8 to 9 months for first-line non-squamous NSCLC, and approximately 7 months for first-line squamous NSCLC. All patients still on treatment have maintained response for approximately 1 year, with exceptionally prolonged responses observed in PD-L1-positive and squamous populations. Two PD-L1-positive patients receiving first-line treatment for non-squamous NSCLC and five patients receiving first-line treatment for squamous NSCLC have all been on treatment for more than 357 days and remain on treatment, demonstrating significant survival benefit advantages and strong competitive potential compared with similar bispecific antibodies. A large number of patients continue to respond with longer follow-up. Compared with the Company's update on the above 18 patients at the 2026 World Conference on Lung Cancer (WCLC) (at which time median follow-up was approximately 10 months), nine patients remain on treatment, with only two additional progressions, consistent with the course of cancer treatment.
Related Articles

HK Stock Market Move | | Airline stocks broadly decline as Brent crude approaches US$93 again; airlines turn cautious on capacity deployment in off-peak season

HK Stock Market Move | Innovative drug concept stocks fell across the board; rate hike expectations weigh on the innovative drug sector; Citi expects medical insurance price cuts to be moderate and manageable.

HK Stock Market Move | CMOC Group Limited (03993) falls over 4%; Citi cuts the company's average selling prices for cobalt and copper, expects valuation attractive amid copper price volatility.
HK Stock Market Move | | Airline stocks broadly decline as Brent crude approaches US$93 again; airlines turn cautious on capacity deployment in off-peak season

HK Stock Market Move | Innovative drug concept stocks fell across the board; rate hike expectations weigh on the innovative drug sector; Citi expects medical insurance price cuts to be moderate and manageable.

HK Stock Market Move | CMOC Group Limited (03993) falls over 4%; Citi cuts the company's average selling prices for cobalt and copper, expects valuation attractive amid copper price volatility.






